Ernexa Therapeutics (ERNAW) Cash from Financing Activities (2011 - 2026)

Ernexa Therapeutics has reported Cash from Financing Activities for 16 years, with the latest figure at $9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 324.09% year-over-year to $9.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (up 103.59% YoY), and the FY2025 full-year result was $7.2 million, up 15.16% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $9.6 million, up from $26000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $12.0 million in Q1 2022, with the low at -$22000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $3.9 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 142233.33% — and 2024, when it sank 107.05%.
• Ernexa Therapeutics' Cash from Financing Activities stood at $7.6 million in 2022, then climbed by 1.46% to $7.7 million in 2023, then tumbled by 86.89% to $1.0 million in 2024, then sank by 97.43% to $26000.0 in 2025, then soared by 36665.38% to $9.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $9.6 million (Q1 2026), $26000.0 (Q3 2025), and $4.9 million (Q2 2025), per Business Quant data.